NEW YORK – An international team of researchers has identified new biological features that could help determine how patients with advanced renal cell carcinoma (aRCC) will respond to combined PD-1/PD-L1 and angiogenic pathway inhibition.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.